Document is current
Any future updates will be listed below
-
Authors
Fletcher, Jane M.
Saunders-Smith, Terry
Manns, Braden J.
Tsuyuki, Ross
Hemmelgarn, Brenda R.
Tonelli, Marcello
Campbell, David J. T. http://orcid.org/0000-0002-5570-3630
-
Funding
Funding for this research was provided by:
Alberta Innovates - Health Solutions (201300672)
University of Calgary Clinical Research Fund (CRF15-018)
Canadian Institute of Health Research - Foundation Grant (148441)
- License Information
-
More Information
Article History
Received: 15 May 2020
Accepted: 7 October 2020
First Online: 31 October 2020
Ethics approval and consent to participate
: The University of Calgary Conjoint Health Research Ethics Board approved both the participant focus groups and the pharmacist interviews, within the purview of the ethics certificate for the ACCESS Trial: REB13–1241. Pharmacists were consented verbally over the phone, and focus group participants gave written consent.
: Not applicable - no identifying data is present.
: The only disclosure is that Dr. Tsuyuki has received investigator-initiated grants from Merck Canada, AstraZeneca Canada, and Sanofi Canada. He has given paid presentations for Merck Canada and Sanofi Canada. These grants and presentations are unrelated to the current manuscript. This manuscript has not been submitted for publication in any other journal.
